STAGE IVB PROSTATE CANCER AJCC V8
Clinical trials for STAGE IVB PROSTATE CANCER AJCC V8 explained in plain language.
Never miss a new study
Get alerted when new STAGE IVB PROSTATE CANCER AJCC V8 trials appear
Sign up with your email to follow new studies for STAGE IVB PROSTATE CANCER AJCC V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New trial aims to delay prostate cancer progression with targeted radiation
Disease control Recruiting nowThis study tests whether adding PET-guided radiation to standard hormone therapy can better control metastatic prostate cancer that still responds to hormones. About 125 men with stage IVB prostate cancer will either receive standard treatment alone or standard treatment plus rad…
Matched conditions: STAGE IVB PROSTATE CANCER AJCC V8
Phase: PHASE2 • Sponsor: Northwestern University • Aim: Disease control
Last updated May 17, 2026 04:41 UTC
-
Could high testosterone boost chemo in tough prostate cancers?
Disease control Recruiting nowThis study tests whether giving high levels of testosterone (much higher than normal) can make chemotherapy or a targeted radiation drug work better in men with advanced prostate cancer that has stopped responding to standard hormone therapy. About 69 participants will receive te…
Matched conditions: STAGE IVB PROSTATE CANCER AJCC V8
Phase: PHASE2 • Sponsor: University of Washington • Aim: Disease control
Last updated May 17, 2026 04:41 UTC
-
Triple therapy may extend lives in metastatic prostate cancer
Disease control Recruiting nowThis study tests whether adding a chemotherapy drug (docetaxel) to the usual hormone therapy plus apalutamide helps men with prostate cancer that has spread to other parts of the body live longer. About 1,260 participants will receive either the standard two-drug treatment or the…
Matched conditions: STAGE IVB PROSTATE CANCER AJCC V8
Phase: PHASE3 • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Disease control
Last updated May 17, 2026 04:39 UTC
-
New targeted radiation shows promise for Tough-to-Treat prostate cancer
Disease control Recruiting nowThis study tests a drug called 177Lu-PSMA-617 in 51 men with advanced prostate cancer that has spread and stopped responding to hormone therapy. The drug delivers a small dose of radiation directly to cancer cells to damage their DNA. The goal is to see if it can slow cancer grow…
Matched conditions: STAGE IVB PROSTATE CANCER AJCC V8
Phase: PHASE2 • Sponsor: University of Washington • Aim: Disease control
Last updated May 17, 2026 04:39 UTC
-
Triple-Drug attack shows promise for rare bladder and kidney cancers
Disease control Recruiting nowThis study tests a combination of three drugs—cabozantinib, nivolumab, and ipilimumab—in people with rare genitourinary cancers that have spread. The goal is to see if this mix can shrink tumors or stop them from growing. About 314 adults with these rare cancers will take part. T…
Matched conditions: STAGE IVB PROSTATE CANCER AJCC V8
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 04:38 UTC
-
New combo therapy aims to slow Tough-to-Treat prostate cancer
Disease control Recruiting nowThis study tests whether adding carboplatin to the standard chemotherapy cabazitaxel helps men with advanced prostate cancer that no longer responds to hormone therapy. About 528 participants will receive either cabazitaxel alone or cabazitaxel plus carboplatin. The goal is to se…
Matched conditions: STAGE IVB PROSTATE CANCER AJCC V8
Phase: PHASE3 • Sponsor: SWOG Cancer Research Network • Aim: Disease control
Last updated May 17, 2026 04:38 UTC
-
Could fewer doses be just as effective for prostate cancer?
Disease control Recruiting nowThis study looks at whether men with advanced prostate cancer that has spread can safely stop treatment after 5 cycles of a targeted radiation drug (177Lu-PSMA-617) instead of the usual 6 cycles. The goal is to see if the shorter plan controls the cancer just as well while reduci…
Matched conditions: STAGE IVB PROSTATE CANCER AJCC V8
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated May 17, 2026 04:35 UTC
-
Can a second dose of radioactive therapy beat back prostate cancer?
Disease control Recruiting nowThis study tests whether giving a second round of a radioactive drug called 177Lu-PSMA-617 can help men with advanced prostate cancer that stopped responding to hormone therapy and chemotherapy. The drug targets and delivers radiation directly to cancer cells. Only patients who h…
Matched conditions: STAGE IVB PROSTATE CANCER AJCC V8
Phase: PHASE2 • Sponsor: Jonsson Comprehensive Cancer Center • Aim: Disease control
Last updated May 17, 2026 04:35 UTC
-
New trial aims to Fine-Tune prostate cancer treatment timing
Disease control Recruiting nowThis study looks at the best timing for combining targeted radiation (SBRT) with hormone therapy in men whose prostate cancer has returned and spread. It also tests if radiation to the pelvis can stop cancer from spreading further. About 532 men with recurrent, hormone-sensitive …
Matched conditions: STAGE IVB PROSTATE CANCER AJCC V8
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated May 17, 2026 04:34 UTC
-
Engineered immune cells take on Hard-to-Treat prostate cancer
Disease control Recruiting nowThis early-stage trial tests a new treatment for men with a type of advanced prostate cancer that no longer responds to hormone therapy. The treatment uses the patient's own immune cells, which are modified in a lab to better recognize and attack cancer cells. Some participants w…
Matched conditions: STAGE IVB PROSTATE CANCER AJCC V8
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 17, 2026 04:34 UTC
-
Two-Drug combo aims to boost immune attack on Hard-to-Treat prostate cancer
Disease control Recruiting nowThis early-stage trial tests whether adding a radioactive drug (177Lu-PSMA-617) to an immune cell therapy (Sipuleucel-T) is safe and works better than the radioactive drug alone for men with advanced prostate cancer that has spread and stopped responding to hormone therapy. About…
Matched conditions: STAGE IVB PROSTATE CANCER AJCC V8
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 15, 2026 11:57 UTC
-
New combo aims to boost radiation's punch against hard-to-treat prostate cancer
Disease control Recruiting nowThis study tests whether giving a drug called abemaciclib before a targeted radiation therapy (177Lu-PSMA-617) can help treat metastatic castration-resistant prostate cancer that has stopped responding to other treatments. Abemaciclib may increase the number of targets (PSMA) on …
Matched conditions: STAGE IVB PROSTATE CANCER AJCC V8
Phase: PHASE1, PHASE2 • Sponsor: Vadim S Koshkin • Aim: Disease control
Last updated May 15, 2026 11:53 UTC
-
Triple-Drug attack aims to halt bone metastases in prostate cancer
Disease control Recruiting nowThis study tests whether adding two newer drugs (M3814 and avelumab) to the standard radioactive drug radium-223 can better control advanced prostate cancer that has spread to bones. About 90 men with castration-resistant prostate cancer will receive either radium-223 alone, radi…
Matched conditions: STAGE IVB PROSTATE CANCER AJCC V8
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 14, 2026 12:05 UTC
-
Could surgery or radiation boost survival in advanced prostate cancer?
Disease control Recruiting nowThis study is for men with prostate cancer that has spread to other parts of the body. It compares standard drug therapy alone versus standard therapy plus surgery to remove the prostate or radiation to the prostate. The goal is to see if adding local treatment helps patients liv…
Matched conditions: STAGE IVB PROSTATE CANCER AJCC V8
Phase: PHASE3 • Sponsor: SWOG Cancer Research Network • Aim: Disease control
Last updated May 12, 2026 13:43 UTC
-
New hope for Hard-to-Treat prostate cancer: drug combo trial launches
Disease control Recruiting nowThis study tests a combination of two drugs, ruxolitinib and enzalutamide, in men with advanced prostate cancer that has spread and no longer responds to hormone therapy. The goal is to find the safest dose and see if the combo can shrink tumors or lower PSA levels. About 20 part…
Matched conditions: STAGE IVB PROSTATE CANCER AJCC V8
Phase: PHASE1, PHASE2 • Sponsor: University of Michigan Rogel Cancer Center • Aim: Disease control
Last updated May 11, 2026 20:49 UTC
-
PET scans guide smarter treatment for recurrent prostate cancer in major trial
Disease control Recruiting nowThis study is for men whose prostate cancer has come back (shown by rising PSA levels) after their prostate was removed. It tests whether using PET scans to guide more personalized treatment—adding the drug apalutamide with or without targeted radiation—works better than standard…
Matched conditions: STAGE IVB PROSTATE CANCER AJCC V8
Phase: PHASE3 • Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Disease control
Last updated May 11, 2026 20:46 UTC
-
Testosterone therapy shows promise for Hard-to-Treat prostate cancer
Disease control Recruiting nowThis early-stage study tests a treatment called bipolar androgen therapy for men with advanced prostate cancer that no longer responds to standard hormone therapy and has spread. The approach rapidly switches testosterone levels from very low to very high to shock cancer cells an…
Matched conditions: STAGE IVB PROSTATE CANCER AJCC V8
Phase: PHASE1 • Sponsor: Roswell Park Cancer Institute • Aim: Disease control
Last updated May 11, 2026 20:39 UTC
-
Engineered immune cells take on Hard-to-Treat prostate cancer
Disease control Recruiting nowThis study tests whether a new cell therapy (STEAP1 CART) combined with the drug enzalutamide is safe and effective for men with advanced prostate cancer that has spread and stopped responding to standard treatments. About 48 participants will receive their own immune cells, modi…
Matched conditions: STAGE IVB PROSTATE CANCER AJCC V8
Phase: PHASE1, PHASE2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated May 06, 2026 16:01 UTC
-
New drug combo shows promise in halting prostate cancer growth
Disease control Recruiting nowThis study tests whether adding a targeted drug called talazoparib to standard hormone therapy can better control prostate cancer that has spread but still responds to hormones. About 70 men with metastatic castration-sensitive prostate cancer will receive the combination. The go…
Matched conditions: STAGE IVB PROSTATE CANCER AJCC V8
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 01, 2026 15:58 UTC
-
New combo aims to make resistant prostate cancer cells visible to targeted radiation
Disease control Recruiting nowThis study tests whether the drug vorinostat can help men with a type of advanced prostate cancer that has low levels of a specific marker (PSMA). The marker is needed for a radioactive therapy called 177Lu-PSMA-617 to work. By giving vorinostat first, the hope is to increase PSM…
Matched conditions: STAGE IVB PROSTATE CANCER AJCC V8
Phase: PHASE2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Apr 30, 2026 15:49 UTC
-
Freeze and zap: new combo therapy aims to crush bone cancer pain
Symptom relief Recruiting nowThis study tests whether freezing bone tumors (cryoablation) before giving radiation therapy works better than radiation alone for reducing pain. About 40 adults with cancer that has spread to the bones will be enrolled. The goal is to see if the combination provides more complet…
Matched conditions: STAGE IVB PROSTATE CANCER AJCC V8
Phase: NA • Sponsor: M.D. Anderson Cancer Center • Aim: Symptom relief
Last updated May 13, 2026 15:58 UTC
-
Can DNA glitches predict prostate cancer treatment success?
Knowledge-focused Recruiting nowThis study looks at men with advanced prostate cancer that has spread to the bones. Researchers want to see if certain DNA repair problems in the cancer affect how well the drug radium-223 works. The goal is to help doctors choose better treatments in the future. About 48 men wil…
Matched conditions: STAGE IVB PROSTATE CANCER AJCC V8
Sponsor: University of Washington • Aim: Knowledge-focused
Last updated May 17, 2026 04:35 UTC
-
DNA-Guided prostate cancer therapy put to the test
Knowledge-focused Recruiting nowThis study is for men with advanced prostate cancer that no longer responds to hormone therapy. Researchers want to see if using genetic tests on tumor tissue can help pick the most effective treatment from several options, including newer targeted drugs and chemotherapy. About 4…
Matched conditions: STAGE IVB PROSTATE CANCER AJCC V8
Phase: PHASE2 • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Knowledge-focused
Last updated May 15, 2026 11:57 UTC
-
Tailored care plans aim to close health literacy gap for black prostate cancer patients
Knowledge-focused Recruiting nowThis study compares a standard survivorship care plan to one that is tailored for people with lower health literacy. The goal is to see if the tailored plan helps African American prostate cancer patients better understand their treatment side effects and follow-up care. About 15…
Matched conditions: STAGE IVB PROSTATE CANCER AJCC V8
Phase: NA • Sponsor: Emory University • Aim: Knowledge-focused
Last updated May 12, 2026 13:40 UTC
-
Biopsies reveal secrets of prostate cancer resistance
Knowledge-focused Recruiting nowThis study looks at why some advanced prostate cancers become resistant to a treatment called 177Lu-PSMA. Researchers will take small tissue samples (biopsies) from tumors during treatment to find genetic changes that cause resistance. The goal is to learn how to make treatments …
Matched conditions: STAGE IVB PROSTATE CANCER AJCC V8
Phase: PHASE1 • Sponsor: Jonsson Comprehensive Cancer Center • Aim: Knowledge-focused
Last updated May 11, 2026 20:53 UTC